Literature DB >> 26354483

Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.

Zane Jaunmuktane1, Simon Mead2,3,4, Matthew Ellis3, Jonathan D F Wadsworth2,3, Andrew J Nicoll2,3, Joanna Kenny2,4, Francesca Launchbury3, Jacqueline Linehan2, Angela Richard-Loendt3, A Sarah Walker5, Peter Rudge2,4, John Collinge2,3,4, Sebastian Brandner1,2,3.   

Abstract

More than two hundred individuals developed Creutzfeldt-Jakob disease (CJD) worldwide as a result of treatment, typically in childhood, with human cadaveric pituitary-derived growth hormone contaminated with prions. Although such treatment ceased in 1985, iatrogenic CJD (iCJD) continues to emerge because of the prolonged incubation periods seen in human prion infections. Unexpectedly, in an autopsy study of eight individuals with iCJD, aged 36-51 years, in four we found moderate to severe grey matter and vascular amyloid-β (Aβ) pathology. The Aβ deposition in the grey matter was typical of that seen in Alzheimer's disease and Aβ in the blood vessel walls was characteristic of cerebral amyloid angiopathy and did not co-localize with prion protein deposition. None of these patients had pathogenic mutations, APOE ε4 or other high-risk alleles associated with early-onset Alzheimer's disease. Examination of a series of 116 patients with other prion diseases from a prospective observational cohort study showed minimal or no Aβ pathology in cases of similar age range, or a decade older, without APOE ε4 risk alleles. We also analysed pituitary glands from individuals with Aβ pathology and found marked Aβ deposition in multiple cases. Experimental seeding of Aβ pathology has been previously demonstrated in primates and transgenic mice by central nervous system or peripheral inoculation with Alzheimer's disease brain homogenate. The marked deposition of parenchymal and vascular Aβ in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of Aβ pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of iatrogenic Alzheimer's disease and cerebral amyloid angiopathy. These findings should also prompt investigation of whether other known iatrogenic routes of prion transmission may also be relevant to Aβ and other proteopathic seeds associated with neurodegenerative and other human diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354483     DOI: 10.1038/nature15369

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  38 in total

Review 1.  Transmissible and non-transmissible amyloidoses: autocatalytic post-translational conversion of host precursor proteins to beta-pleated sheet configurations.

Authors:  D C Gajdusek
Journal:  J Neuroimmunol       Date:  1988-12       Impact factor: 3.478

2.  PrP glycoforms are associated in a strain-specific ratio in native PrPSc.

Authors:  Azadeh Khalili-Shirazi; Linda Summers; Jacqueline Linehan; Gary Mallinson; David Anstee; Simon Hawke; Graham S Jackson; John Collinge
Journal:  J Gen Virol       Date:  2005-09       Impact factor: 3.891

3.  The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain.

Authors:  Tsuyoshi Hamaguchi; Yvonne S Eisele; Nicholas H Varvel; Bruce T Lamb; Lary C Walker; Mathias Jucker
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

Review 4.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

5.  Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease.

Authors:  J A Hainfellner; J Wanschitz; K Jellinger; P P Liberski; F Gullotta; H Budka
Journal:  Acta Neuropathol       Date:  1998-08       Impact factor: 17.088

6.  Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.

Authors:  H F Baker; R M Ridley; L W Duchen; T J Crow; C J Bruton
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

7.  Molecular diagnosis of human prion disease.

Authors:  Jonathan D F Wadsworth; Caroline Powell; Jonathan A Beck; Susan Joiner; Jacqueline M Linehan; Sebastian Brandner; Simon Mead; John Collinge
Journal:  Methods Mol Biol       Date:  2008

8.  Aβ seeds resist inactivation by formaldehyde.

Authors:  Sarah K Fritschi; Amarallys Cintron; Lan Ye; Jasmin Mahler; Anika Bühler; Frank Baumann; Manuela Neumann; K Peter R Nilsson; Per Hammarström; Lary C Walker; Mathias Jucker
Journal:  Acta Neuropathol       Date:  2014-09-06       Impact factor: 17.088

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice.

Authors:  Florence Clavaguera; Jürgen Hench; Isabelle Lavenir; Gabriel Schweighauser; Stephan Frank; Michel Goedert; Markus Tolnay
Journal:  Acta Neuropathol       Date:  2013-12-21       Impact factor: 17.088

View more
  175 in total

Review 1.  Genetic PrP Prion Diseases.

Authors:  Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

2.  Neurodegeneration: Amyloid-β pathology induced in humans.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2015-09-10       Impact factor: 49.962

Review 3.  β-Amyloid Prions and the Pathobiology of Alzheimer's Disease.

Authors:  Joel C Watts; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

4.  Alpha-synuclein: prion or prion-like?

Authors:  Rehana K Leak; Matthew P Frosch; Thomas G Beach; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2019-08-12       Impact factor: 17.088

5.  Is Alzheimer's Disease Transmissible in Humans?

Authors:  Xian-Le Bu; Wei-Wei Li; Yan-Jiang Wang
Journal:  Neurosci Bull       Date:  2019-04-29       Impact factor: 5.203

6.  Follow-up study of a patient with early onset cerebral amyloid angiopathy following childhood cadaveric dural graft.

Authors:  Kenji Yoshiki; Genjiro Hirose; Kazuhiko Kumahashi; Yukihiko Kohda; Kazunori Ido; Akihiro Shioya; Kouichi Misaki; Kensaku Kasuga
Journal:  Acta Neurochir (Wien)       Date:  2021-02-13       Impact factor: 2.216

7.  Organizing biochemistry in space and time using prion-like self-assembly.

Authors:  Christopher M Jakobson; Daniel F Jarosz
Journal:  Curr Opin Syst Biol       Date:  2017-12-06

Review 8.  Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature.

Authors:  Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

9.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

Review 10.  Developing therapeutic vaccines against Alzheimer's disease.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Expert Rev Vaccines       Date:  2015-12-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.